Source-grounded facts extracted from Clene Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Clene Inc. shareholders approved Amendment to Clene Inc. Amended 2020 Stock Plan to increase reserved shares by 1,000,000 at the 2026-05-21 meeting.
“4. An amendment to the Clene Inc. Amended 2020 Stock Plan was approved, thus increasing the number of shares of Common Stock reserved for issuance thereunder by 1,000,000 shares, based upon the following votes: For Against Abstained Broker Non-Votes 4,204,336 475,626 15,747 3,057,461”
Clene Inc. shareholders approved Advisory vote on compensation of Named Executive Officers at the 2026-05-21 meeting.
“3. The compensation of the Company's Named Executive Officers was approved, on an advisory basis, based upon the following votes: For Against Abstained Broker Non-Votes 3,973,504 660,734 61,471 3,057,461”
Clene Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-05-21 meeting.
“2. The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for fiscal year 2026 was ratified based upon the following votes: For Against Abstained 7,737,513 11,372 4,285”
Clene Inc. shareholders approved Election of Class III directors at the 2026-05-21 meeting.
“1. The following nominees were elected to serve as Class III directors until the expiration of their three-year term at the annual meeting of stockholders in 2029, or until their successors are duly elected and qualified, based upon the following votes: For Withheld Broker Non-Votes Robert Etherington 3,904,259 791,450 3,057,461 Shalom Jacobovitz 3,711,448 984,261 3,057,461 Alison H. Mosca 3,675,073 1,020,636 3,057,461”
Clene Inc. amended First Amendment to August 2025 Senior Secured Convertible Promissory Notes with AE Capital Limited, A Global Chorus Foundation and Glenn and Shelina Way valued at Extension of maturity date to earlier of August 13, 2027 or change in control; deferral of $150,000 (effective 2026-05-18).
“On May 18, 2026, Clene Inc. (the “Company”) entered into an amendment (the “Amendment”) to the senior secured convertible promissory notes (the “Notes”) with AE Capital Limited, A Global Chorus Foundation and Glenn and Shelina Way.”
Clene Inc. amended Second Amendment with Kensington Clene 2024, LLC, 4Life Research, LLC, La Scala Investments, LLC (effective 2026-05-11).
“On May 11, 2026, Clene Inc. (the “Company”) entered into the second amendment (the “Second Amendment”) to the amended and restated senior secured convertible promissory notes (the “Amended Notes”) with Kensington Clene 2024, LLC (“Kensington”), 4Life Research, LLC (“4Life”) and La Scala Investments, LLC (“La Scala,” and collectively with Kensington and 4Life, the “Holders”).”
Clene Inc. reported first quarter 2026 results: net income net loss of $8.1 million , or $0.69 per share, EPS $0.69 per share.
“Clene reported a net loss of $8.1 million , or $0.69 per share, for the quarter ended March 31, 2026 , compared to a net loss of $0.8 million , or $0.09 per share, for the same period in 2025 .”
Clene Inc. entered into Underwriting Agreement with Canaccord Genuity LLC valued at 1,000,000 shares of common stock at $7.00 per share for estimated net proceeds of $6.4 million (effective 2026-05-05).
“On May 5, 2026, Clene Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Canaccord Genuity LLC as underwriter, pursuant to which the Company agreed to issue and sell an aggregate of 1,000,000 shares of the Company’s common stock, par value $0.0001 per share (“common stock”), at an offering price of $7.00 per share.”
Clene Inc. entered into Year 3 Subaward with New York University (NYU) valued at up to $8.0 million (effective 2026-03-13).
“On March 13, 2026, the Company entered into a subaward agreement for the third year of the NIH Grant with New York University (“NYU”), the prime awardee, for up to $8.0 million during the period from September 1, 2025 to August 31, 2026 (the “Year 3 Subaward”).”
Clene Inc. entered into Securities Purchase Agreement with certain institutional investors, existing stockholders of the Company, and certain of the Company's directors valued at $6.50 per unit (effective 2026-01-08).
“On January 8, 2026, Clene Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors, existing stockholders of the Company, and certain of the Company’s directors for the sale of (i) 928,333 shares of the Company’s common stock, par value $0.0001 per share (“common stock”), (ii) warrants to purchase up to 1,114,000 shares of the Company’s common stock (the “Series A Warrants”) and (iii) warrants to purchase up to 2,599,333 shares of the Company’s common stock (the “Series B Warrants,” and together with the Series A Warrants, the “Warrants”).”
Clene Inc. incurred convertible notes of $1,500,000 aggregate principal amount with AE Capital Limited; A Global Chorus Foundation; Glenn and Shelina Way at 12% per annum, interest capitalized and added to principal balance maturing earlier of 18 months from closing or Change in Control.
“On August 13, 2025, the Company entered into a note purchase agreement (the “August 2025 Note Purchase Agreement”) by and among the Company and AE Capital Limited, A Global Chorus Foundation and Glenn and Shelina Way (together with AE Capital Limited and A Global Chorus Foundation, the “August 2025 Note Purchasers”), pursuant to which the Company agreed to sell, and the August 2025 Note Purchasers agreed to purchase, the Company’s senior secured convertible promissory notes (collectively, the “ August 2025 Notes”) in a principal amount totaling $1,500,000.”
Clene Inc. amended convertible notes of original principal amounts unchanged (December 2024 Notes); monthly principal repayments of $1,000,000 per month deferre with Kensington Clene 2024, LLC; 4Life Research, LLC; La Scala Investments, LLC at interest capitalized and added to balance from August 1, 2025; at holder electio maturing maturity extended to earlier of February 13, 2027 or Change in Control.
“On August 13, 2025, Clene Inc. (the “Company”) entered into the first amendment (the “Amendment”) to the senior secured convertible promissory notes (collectively, the “December 2024 Notes”) which were issued by the Company on December 17, 2024 to Kensington Clene 2024, LLC (“Kensington”), 4Life Research, LLC (“4Life”) and La Scala Investments, LLC (“La Scala,” and collectively with Kensington and 4Life, the “December 2024 Note Purchasers”).”
Clene Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).
“May 6, 2025, the Company received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that for the last 30 consecutive business days, the Market Value of Listed Securities (“MVLS”) for the Company’s common stock was below the minimum $35.0 million requirement for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “Minimum MVLS Requirement”). Additionally, the Company does not meet either of the alternative Nasdaq continued listing standards under Nasdaq Listing Rule 5550(b)(2): (i) stockholders’ equity of at least $2.5 million”
Clene Inc. reported first quarter 2024 results: net income net loss of $11.1 million, EPS $0.09 per share.
“Clene reported a net loss of $11.1 million , or $0.09 per share, for the quarter ended March 31, 2024”
Clene Inc. entered into Amended and Restated License Agreement with 4Life Research, LLC valued at exclusive, royalty bearing license; royalty rate 3% of incremental sales; term through 2033 (effective 2024-04-25).
“On April 25, 2024, Clene Inc. and its wholly owned subsidiary, Clene Nanomedicine, Inc. (together with Clene Inc. and its other subsidiaries, the “Company”), entered into an amended and restated exclusive supply agreement (the “Supply Agreement”) and an amended and restated license agreement (the “License Agreement” and, collectively with the Supply Agreement, the “Amended 4Life Agreements”) with 4Life Research, LLC (“4Life”), an international supplier of health supplements, stockholder, and related party.”
Clene Inc. entered into Amended and Restated Exclusive Supply Agreement with 4Life Research, LLC valued at cost plus 20% purchase price; Minimum Sales Commitments through 2033; royalty rate 3% of incremental (effective 2024-04-25).
“On April 25, 2024, Clene Inc. and its wholly owned subsidiary, Clene Nanomedicine, Inc. (together with Clene Inc. and its other subsidiaries, the “Company”), entered into an amended and restated exclusive supply agreement (the “Supply Agreement”) and an amended and restated license agreement (the “License Agreement” and, collectively with the Supply Agreement, the “Amended 4Life Agreements”) with 4Life Research, LLC (“4Life”), an international supplier of health supplements, stockholder, and related party.”
Clene Inc. entered into Subaward with Colombia University valued at up to $7.3 million (effective 2024-04-03).
“On April 3, 2024, the Company entered into a grant subaward agreement (the “Subaward”) with Colombia pursuant to the NIH Grant.”
Clene Inc. reported financial results for the year ended December 31, 2023.
“On March 13, 2024, Clene Inc. (the “Company”) issued a press release announcing its full year operating and financial results for its year ended December 31, 2023.”
Clene Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“January 30, 2024, the Company received a notice from Nasdaq that, while the Company has not regained compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A), it is eligible for an additional 180 calendar day period, or until July 29, 2024, to regain compliance with the Minimum Bid Price Requirement (the “January Notice”). The January Notice has no immediate effect on the listing of the Company’s common stock and its common stock will continue to be listed on the Nasdaq Capital Market under the symbol “CLNN.” Nasdaq’s determination to grant an add”
Clene Inc. reported third quarter 2023 results: net income $2.4 million, EPS $0.02 per share.
“Clene reported a net loss of $2.4 million, or $0.02 per share, for the quarter ended September 30, 2023”
John H. Stevens retired as Class II Director at Clene Inc..
“John H. Stevens, M.D., a Class II director of the Company, informed the Board of his decision to retire from the Board and all committees”
Arjun Desai was appointed as Class II Director at Clene Inc..
“appointed Professor Matthew Kiernan AM, Ph.D., DSc, and Arjun (JJ) Desai, M.D., as members of the Board, effective September 18, 2023.”
Matthew Kiernan was appointed as Class II Director at Clene Inc..
“appointed Professor Matthew Kiernan AM, Ph.D., DSc, and Arjun (JJ) Desai, M.D., as members of the Board, effective September 18, 2023.”
Clene Inc. reported second quarter 2023 results: net income $25.1 million, EPS $0.29 per share.
“Clene reported a net loss of $25.1 million , or $0.29 per share, for the quarter ended June 30, 2023”
Clene Inc. amended Second Amendment to Supplement to Loan and Security Agreement with Avenue Venture Opportunities Fund, L.P. valued at Amendment extends interest-only period to June 30, 2024 (subject to $35M equity milestone) or Decemb (effective 2023-06-27).
“if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01 Entry into a Material Definitive Agreement. On June 27, 2023 (the “Effective Date”) , Clene Inc. and its wholly owned subsidiary, Clene Nanomedicine, Inc. (together with Clene Inc. and its other subsidiaries, the “Company”), entered into the Second Amendment to Supplement to Loan and Security Agreement (the “Second Amendment”) by and among Avenue Venture Opportunities Fund, L.P. (“Avenue”) and the Company. The Company originally entered into the Loan and Security Agreement (the “Loan”) with Avenue on May 21, 2021. Pursuant to the Second Amendment, the interest-only period of the Loan may be extended (i) through June 30, 2024, subject to the Company’s receipt of at least thirty-five million dollars ($35,000,000) in June 2023 from the sale and issuance of the Company’s equity securi”
Clene Inc. entered into Underwriting Agreement with Canaccord Genuity LLC (effective 2023-06-16).
“On June 16, 2023, Clene Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Canaccord Genuity LLC (“Canaccord”) as underwriter, pursuant to which the Company agreed to issue and sell, in an equity offering (the “Offering”), an aggregate of (i) 50,000,000 shares of its common stock, par value $0.0001 per share (“Common Stock”), (ii) warrants to purchase up to 50,000,000 shares of Common Stock at an exercise price of $1.10 per whole share of Common Stock (the “Tranche A Warrants”), and (iii) warrants to purchase up to 50,000,000 shares of Common Stock at an exercise price of $1.50 per whole share of Common Stock (the “Tranche B Warrants,” and collectively with the Tranche A Warrants, the “Warrants”).”
Clene Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“May 31, 2023, Clene Inc. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing in the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Notice has no immediate effect on the listing of the Company’s common stock and its common stock will continue to be listed on the Nasdaq Capital Market under the symbol “CLNN.” In accord”
Clene Inc. reported first quarter ended March 31, 2023 results: net income $11.8 million, EPS $0.15 per share.
“Clene reported a net loss of $11.8 million , or $0.15 per share, for the quarter ended March 31, 2023, compared to a net loss of $13.4 million , or $0.21 per share, for the same period in 2022.”
Clene Inc.: Increased number of authorized shares of Common Stock from 150,000,000 to 300,000,000 (effective 2023-05-09).
“the stockholders of the Company adopted the Fourth Amended and Restated Certificate of Incorporation (the “Certificate”) to increase the number of authorized shares of Common Stock from 150,000,000 to 300,000,000. The Certificate became effective upon filing with the Secretary of State of the State of Delaware on May 9, 2023.”
Clene Inc. shareholders approved Approval of Amended 2020 Stock Plan to increase shares reserved by 6,400,000 at the 2023-05-09 meeting.
“The Amended 2020 Stock Plan of the Company was approved, thus increasing the number of shares of Common Stock reserved for issuance thereunder by 6,400,000 shares, based upon the following votes: For Against Abstained Broker Non-Votes 45,180,340 890,806 6,289 8,248,354”
Clene Inc. shareholders approved Adoption of Fourth Amended and Restated Certificate of Incorporation to increase authorized shares of Common Stock to 300,000,000 at the 2023-05-09 meeting.
“The Fourth Amended and Restated Certificate of Incorporation of the Company was adopted, thus increasing the number of authorized shares of Common Stock to 300,000,000, based upon the following votes: For Against Abstained 52,970,818 1,346,239 8,732”
Clene Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-05-09 meeting.
“The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for fiscal year 2023 was ratified based upon the following votes: For Against Abstained 54,225,639 88,969 11,181”
Clene Inc. shareholders approved Election of Class III directors at the 2023-05-09 meeting.
“The following nominees were elected to serve as Class III directors until the expiration of their three-year term at the annual meeting of stockholders in 2026 or until their successors are duly elected and qualified, based upon the following votes: For Withheld Broker Non-Votes Robert Etherington 45,626,260 451,175 8,248,354 Shalom Jacobovitz 45,472,210 605,225 8,248,354 Alison H. Mosca 45,456,076 621,359 8,248,354”
Robert Glanzman retired as Chief Medical Officer at Clene Inc..
“On March 15, 2023, Robert Glanzman, M.D., FAAN, the Chief Medical Officer of Clene Inc. (the “Company”), notified the Company of his intent to retire from his position, effective as of April 1, 2023 (the “Effective Date”).”
Clene Inc. reported financial results for full year ended December 31, 2022.
“On March 13, 2023, Clene Inc. (the “Company”) issued a press release announcing its full year operating and financial results for its year ended December 31, 2022.”
Clene Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $25,000,000 (effective 2023-03-03).
“On March 3, 2023, Clene Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park has committed to purchase up to $25,000,000 of shares (the “Purchase Shares”) of the Company's common stock”
Chidozie Ugwumba resigned as Class II director at Clene Inc..
“On February 15, 2023, Chidozie Ugwumba, a Class II director of Clene Inc. (the “Company”), informed the Board of Directors of the Company (the “Board”) of his decision to resign from the Board and all committees thereof, effective immediately.”
Clene Inc. incurred loan of $5.0 million with Department of Housing and Community Development at 6.0% maturing 60 months from the first day of the second full month following the Closing Date.
“The Loan Agreement provides for a loan in the principal amount of $5.0 million (the “Loan”) to support the development of and commercialization of CNM-Au8 and the expansion of the Company’s manufacturing operations. The Company agreed to repay the Loan plus interest at an annual interest rate of 6.0%. The Loan matures on the date that is 60 months from the first day of the second full month following the Closing Date (the “Maturity Date”).”
Clene Inc. entered into Loan Agreement with Department of Housing and Community Development, State of Maryland valued at $5.0 million (effective 2022-12-08).
“On December 8, 2022 (the “Closing Date”), Clene Nanomedicine, Inc. (“Clene”), a wholly owned subsidiary of Clene Inc. (along with its subsidiaries, the “Company”), entered into a loan agreement (the “Loan Agreement”) and promissory note (the “ Promissory Note”) with the Department of Housing and Community Development, a principal department of the State of Maryland (the “DHCD”).”
Clene Inc. reported the quarter ended September 30, 2022 results: net income $11.0 million, EPS $0.17 per share.
“Clene reported a net loss of $11.0 million, or $0.17 per share, for the quarter ended September 30, 2022, compared to net income of $28.9 million, or $0.47 per basic share and $0.42 per diluted share, for the same period in 2021.”
Clene Inc. entered into Securities Purchase Agreement with certain of the Company’s existing stockholders, including stockholders affiliated with directors of the Company (the “Purchasers”) valued at approximately $10.8 million (effective 2022-10-31).
“On October 31, 2022, Clene Inc. (the “Company”) entered into securities purchase agreement (the “Securities Purchase Agreement”) with certain of the Company’s existing stockholders, including stockholders affiliated with directors of the Company (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), 10,723,926 shares of common stock, par value $0.0001 per share, at a sale price of $1.01 per share.”
Morgan Brown was appointed as Chief Financial Officer at Clene Inc..
“On February 1, 2022, Clene Inc. (the “Company”) announced the hiring and appointment of Morgan Brown as its Chief Financial Officer, effective February 1, 2022.”
Vallerie V. McLaughlin, M.D. was appointed as Director at Clene Inc..
“On August 5, 2021, the Board of Directors (the “Board”) of Clene Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Vallerie V. McLaughlin, M.D. as a member of the Board, effective August 5, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.